Physiological and therapeutic roles of peroxisome proliferator-activated receptors

Diabetes Technology and Therapeutics

Volumn 4, Issue 2, 2002, Pages 163-174

  Berger, Joel ^a   Wagner, John A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; BEZAFIBRATE; CLOFIBRATE; CLOFIBRATE DERIVATIVE; FARGLITAZAR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; L 796449; L 805645; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PIRINIXIC ACID; RETINOID X RECEPTOR; ROSIGLITAZONE; TRANSCRIPTION FACTOR; TROGLITAZONE; UNCLASSIFIED DRUG; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; CELL RECEPTOR; LIGAND; RETINOIC ACID RECEPTOR;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CHRONIC DISEASE; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DYSLIPIDEMIA; GENE EXPRESSION REGULATION; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIGAND BINDING; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; GENETICS; HYPERLIPIDEMIA; PHYSIOLOGY; PROMOTER REGION;

ANIMALS; DIABETES MELLITUS; GENE EXPRESSION REGULATION; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; LIGANDS; PROMOTER REGIONS (GENETICS); RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; TRANSCRIPTION FACTORS;

EID: 0035998737     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/15209150260007381     Document Type: Review

References (100)

1. Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPARγ) gene: Alternative promoter use and different splicing yield two mPPARg isoforms
2. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma1 and gamma2
3. The organization, promoter analysis, and expression of the human PPARgamma gene
4. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
5. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor
6. Differential expression of peroxisome proliferator activated receptor (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat
7. α in humans
8. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages
9. alpha) in primary cultures of human vascular endothelial cells
10. gamma activators
11. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?
12. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acid
13. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors
14. Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators
15. Rat PPARs: Quantitative analysis in adult rat tissues and regulation in fasting and refeeding
16. Evolution of the nuclear receptor gene superfamily
17. Coactivator and corepressor complexes in nuclear receptor function
18. From ligand to response: Generating diversity in nuclear receptor coregulator function
19. Functional antagonism between CCAAT/enhancer binding protein-alpha and peroxisome proliferator-activated receptor-gamma on the leptin promoter
20. beta-hydroxysteroid dehydrogenase type 1 expression and activity
21. Enhancement of adipocyte differentiation by an insulin-sensitizing agent
22. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells
23. Localization of a pioglitazone response element in the adipocyte fatty acid binding protein gene
24. mPPARgamma 2: Tissue-specific regulator of an adipocyte enhancer
25. An antidiabetic thiazolidinedione is a high-affinity ligand for peroxisome proliferator-activated receptor γ
26. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: Binding and activation correlate with anti-diabetic actions in db/db mice
27. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones
28. Peroxisome proliferator-activated receptor (PPAR) γ agonists for diabetes
29. The PPARs: From orphan receptors to drug discovery
30. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: Effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats
31. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs
32. Modification and distribution of lipids by ethylchlorophenoxyisobutyrate
33. (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2 ethoxypropanoic acid [(-)DRF 2725]: A dual PPAR agonist with potent antihyperglycemic and lipid-modulating activity
34. Structure of the pparalpha and -gamma ligand binding domain in complex with az 242; ligand selectivity and agonist activation in the ppar family
35. Novel PPARg and PPARd ligands produce distinct biological effects
36. Activation of PPARd alters lipid metaboism in db/db mice
37. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport
38. Stimulation of adipogenesis in fibroblasts by PPAR γ2, a lipid activated transcription factor
39. PPAR gamma is required for placental, cardiac, and adipose tissue development
40. PPARgamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance
41. PPARgamma is required for the differentiation of adipose tissue in vivo and in vitro
42. gamma2: Tissue-specific regulator of an adipocyte enhancer
43. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor γ
44. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter
45. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene
46. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators
47. Regulation of FAT/CD36 gene expression: Further evidence in support of a role of the protein in fatty acid binding/transport
48. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes
49. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma
50. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance
51. Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance
52. Thiazolidine-diones block tumor necrosis factor-alpha-induced inhibition of insulin signaling
53. Muscle and adipose tissue morphology and metabolism in Cushing's syndrome
54. Body fat distribution measured with CT: Correlations in healthy subjects, patients with anorexia nervosa, and patients with Cushing syndrome
55. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice
56. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
57. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients
58. Induction of Acrp30 levels by PPARgamma agonists: A potential mechanism of insulin sensitization
59. Adipose tissue is required for the antidiabetic, but not the hypolipidemic, effect of thiazolidinediones
60. Role of skeletal muscle in thiazolidinedione insulin sensitizer action
61. An antidiabetic thiazolidinedione potentiates insulin stimulation of glycogen synthase in rat adipose tissue
62. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability
63. The hormone resistin links obesity to diabetes
64. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner
65. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors
66. The mouse peroxisome-proliferator-activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene
67. Diverse peroxisome proliferator-activated receptors bind to the peroxisome proliferator-responsive elements of the rat hydratase/dehydrogenase and fatty acyl-CoA oxidase genes but differentially induce expression
68. Characterization of protein-DNA interactions within the peroxisome proliferator-responsive element of the rat hydratase-dehydrogenase gene
69. Emerging concepts in metabolic abnormalities associated with coronary artery disease
70. Distribution of lipids in 8,500 men with coronary artery disease
71. Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk
72. Conclusions from the VA-HJT study
73. Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal acyl co-enzyme A oxidase
74. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells
75. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells
76. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes
77. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators
78. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and non-diabetic low-density lipoprotein receptor-deficient mice
79. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
80. Troglitazone inhibits atherosclerosis in apoliporotein E-knockout mice
81. Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits
82. PPARα and PPARγ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
83. A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis
84. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response
85. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies
86. Hypertension in diabetes mellitus
87. Etiology and prevalence of hypertension in diabetic patients
88. Cardiac and glycemic benefits of troglitazone treatment in NIDDM
89. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives
90. Rosiglitazone-mediated reductions in urinary albumin excretion are associated with changes in ambulatory blood pressure in type 2 diabetes patients
91. Pioglitazone is superior to acarbose in improving glycemic control in patients with type 2 diabetes
92. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
93. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone
94. Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity
95. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus
96. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function
97. Hypertension and insulin resistance: Role of peroxisome proliferator-activated receptor gamma
98. gamma on vascular endothelial function
99. Mechanisms of vasorelaxation induced by troglitazone, a novel antidiabetic drug, in the porcine coronary artery
100. 2+ currents and not endothelial nitric oxide production